Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$112.05 USD
+5.73 (5.39%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $112.09 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Brokerage Reports
Jazz Pharmaceuticals PLC [JAZZ]
Reports for Purchase
Showing records 221 - 240 ( 249 total )
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Favorable Markman Hearing; Reiterate Buy and $63 PT
Provider: WALLACHBETH CAPITAL, LLC
Analyst: YANG D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Initiating Coverage
Provider: Guggenheim Securities LLC
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Reiterate Buy and raise PT from $57 to $64; Q1 beat and raise; EUSA to add $0.75-$0.85 EPS in 2013
Provider: AURIGA USA
Analyst: YANG D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Reiterate Buy and $57 PT; JAZZ to acquire EUSA for $650 million cash
Provider: AURIGA USA
Analyst: YANG D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Reiterate BUY and $57 PT; Could Prialt reach $150 million in revenue by 2016?
Provider: AURIGA USA
Analyst: YANG D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Another Consensus-beating Quarter; Reiterate BUY and Raise Price Target from $55 to $57
Provider: AURIGA USA
Analyst: YANG D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Inline Q3; Visible benefit of Azur acquisition expected in 2013; Reiterate BUY and $55 PT
Provider: AURIGA USA
Analyst: YANG D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
A successful orphan drug story. Initiate coverage with BUY rating and $55 PT
Provider: AURIGA USA
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Dropping Coverage of Biotechnology Stocks
Provider: CAPSTONE INVESTMENTS
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
KEY TAKEAWAY FROM CONFERENCE CALL ON IP protection of REMS program
Provider: CAPSTONE INVESTMENTS
Analyst: YANG D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Another good performance quarter, upsides priced in, Maintain HOLD
Provider: CAPSTONE INVESTMENTS
Analyst: YANG D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
2011 guidance in line with our prior estimates, Maintain Hold Rating
Provider: CAPSTONE INVESTMENTS
Analyst: YANG D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
KEY TAKEAWAYS FROM DISCUSSION ON M&A TRENDS IN PHARMACEUTICALS-BIOTECH INDUSTRY.
Provider: CAPSTONE INVESTMENTS
Analyst: YANG D